About Sigyn Therapeutics
We are a publicly traded company established on the belief that device-based therapies can be engineered to address significant unmet needs in global health. This belief is reflected through our development of Sigyn Therapy™, a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream. Based on these capabilities, Sigyn Therapy™ is a candidate to address pathogen-associated conditions that precipitate sepsis and other life-threatening inflammatory conditions.
Timeline of Corporate Events
- October 2019 – Sigyn Therapeutics, Inc. is incorporated in the State of Delaware by Jim Joyce and Craig Roberts.
- October 2020 – 100% of the outstanding shares of Sigyn Therapeutics are acquired through a public merger transaction with Reign Resources Corporation. Reign subsequently changes its name to Sigyn Therapeutics, Inc. and begins trading under the ticker symbol “SIGY”.
- December 2020 – Reported the first in vitro study results of Sigyn Therapy. The study demonstrated the simultaneous reduction of endotoxin, a gram-negative bacterial toxin, and relevant pro-inflammatory cytokines from human blood plasma. Included among validated cytokines were Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a).
- January 2021 - Announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy to address CytoVesicles (extracellular vesicles that transport inflammatory cargos in the bloodstream).
- January 2021 - Appointed industry veteran Eric Lynam as Head of Clinical Affairs, with a mandate to oversee clinical studies of Sigyn Therapy.
- April 2021 - Disclosed in vitro study observations that demonstrated the ability of Sigyn Therapy to adsorb viral pathogens, including SARS-CoV-2 (COVID-19).
- April 2021 - Appointed former Aethlon Medical executive Charlene Owen as Director of Operations.
- July 2021 - Announced the completion of in vitro blood purification studies that demonstrated the broad-spectrum ability of Sigyn Therapy to eliminate hepatic toxins (ammonia, bile acid & bilirubin) associated with Hepatic Encephalopathy (“HE”).
- July 2021 - Disclosed the completion of a first-in-mammal pilot animal study that validated the feasibility of a clinical protocol that resulted in the safe administration of Sigyn Therapy during six-hour treatment exposures.
- December 2021 - Announced the completion of in vitro studies that validated the ability of Sigyn Therapy to deplete gram-positive bacterial toxins from human blood plasma.
- February 2022 - Reported the successful completion of an in vivo animal study conducted at the University of Michigan, which demonstrated Sigyn Therapy to be safe and well tolerated.
- March 2022 - Appointed accomplished financial executive, Jeremy Ferrell, CPA, MBA as Chief Financial Officer, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping to manage the Company’s relationships and interactions with the investment community.
- March 2022 - Announced the appointments of two internationally recognized clinician researchers, Alexander S. Yevzlin, MD, FASN and H. David Humes, MD, to Sigyn Therapeutics’ Scientific Advisory Board.
- March 2022 - Ajay Verma, MD, PhD, a recognized thought leader in the field of neurology joins the Science Advisory Board.
- April 2022 - Donald J. Hillebrand, M.D., a recognized thought leader in the field of Hepatology and Liver Transplantation joins the Science Advisory Board.
View Therapeutic Opportunities
50+ Years of Relevant Industry Experience
Our co-founders Jim Joyce and Craig Roberts have 50+ years of combined experience in the medical technology field. Additionally, Mr. Joyce has two decades of public company CEO and Corporate Board leadership experience.